Physician profile
Peter C Chi
NPI 1023090867
$16,191.03
in general payments reported to CMS, 2019-2025
47 companies · $2,162 in 2025
The $2,162 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,109 · 2020: $1,625 · 2021: $1,856 · 2022: $2,378 · 2023: $3,364 · 2024: $2,697 · 2025: $2,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,223.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,608.75 | 2019-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals Lp | $1,410.09 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Medtronic Vascular, INC. | $1,302.53 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $1,239.84 | 2019-2024 | Xarelto |
| Abbvie INC. | $1,122.07 | 2019-2025 | Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,024.41 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $954.57 | 2021-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $776.89 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $770.10 | 2020-2025 | Austedo Xr, Austedo Xr |
| Glaxosmithkline, LLC. | $743.67 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $500.05 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boston Scientific Corporation | $410.24 | 2019-2025 | Intracept |
| Eisai INC. | $405.70 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $316.68 | 2022-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $290.00 | 2024-2025 | Voquezna |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Chi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.